FDA Approved Gazyva for Nephrotic Syndrome Treatment
Regulators cleared the drug for patients aged 2 and older with relapsing or steroid-dependent kidney disease.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you trust the FDA's current process for approving new medical treatments?
The FDA has officially approved Gazyva to treat idiopathic nephrotic syndrome in patients 2 years of age and older who are in remission. The treatment is administered via intravenous injection to manage this kidney disorder of unknown cause.
Why it matters
This approval provides a new therapeutic option for children and adults struggling with frequently relapsing or steroid-dependent forms of the disease. It allows patients who have achieved remission to maintain stability with a targeted clinical approach.
The INSHORE Phase 3 study involved 85 patients to test Gazyva efficacy against the standard of care. The drug targets a urine protein-creatinine ratio of no more than 0.2 g/g by the 52-week assessment mark.
The players
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and biological products.
The details
Patients receive the treatment through intravenous injections dosed by weight on Days 1 and 15, followed by subsequent doses at Weeks 24 and 26. While the drug demonstrates clinical success, the label includes boxed warnings regarding hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Timeline
The FDA granted approval for the use of Gazyva on September 25, 2026.
Clinical efficacy was measured against a primary endpoint at Week 52.
The Big Picture
The FDA approval follows the evidence established by the INSHORE phase 3 study, which evaluated therapeutic outcomes in pediatric and adult nephrotic syndrome populations. This decision highlights the increasing use of monoclonal antibody treatments for rare kidney disorders.
Patients who meet the criteria should consult with their healthcare providers regarding the administration schedule and the risks associated with potential side effects like neutropenia or infections. The treatment requirement that patients must be in remission before starting therapy will dictate specific timing for clinical intervention.
The takeaway
Gazyva provides a new pathway for managing idiopathic nephrotic syndrome in eligible patients, though its use requires careful monitoring for severe side effects. Patients should maintain regular communication with their medical teams to manage infusion schedules and potential safety warnings.
Further reading
Learn more about the latest developments in Cancer treatment and research.
More information
View the FDA drug approval press release for complete clinical documentation.
Live Poll
Do you trust the FDA's current process for approving new medical treatments?
